Live from the Lab! - Fresh from presenting multiple studies at the 2025 Digestive Disease Week (DDW) Conference, Dr. Mark Pimentel shared new insights in SIBO and IBS research, testing advances, and treatment approaches – and answered viewer questions during a Live Q&A.

 About Mark Pimentel, MD: 🔬 Dr. Mark Pimentel is a renowned gastroenterologist and researcher, serving as the Executive Director of the Medically Associated Science and Technology (MAST) program at Cedars-Sinai. He is widely recognized for his pioneering work on IBS and SIBO, having published over 150 scientific papers and authored two books on the subjects. Dr. Pimentel's research has led to significant advancements in understanding the relationship between gut microbiome and gastrointestinal disorders, resulting in the development of new diagnostic tests and treatment approaches.

>> Watch the entire video on YouTube

Webinar was originally sponsored by Gemelli Biotech

The breath tests (lactulose and glucose) for SIBO have been shown to be unreliable with high false positive and poor sensitivity. The gold standard for detecting SIBO is to take a sample from the jejunum during an endoscopy and culture it.

𝐂𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐚𝐩𝐩𝐫𝐚𝐢𝐬𝐚𝐥 𝐨𝐟 𝐭𝐡𝐞 𝐒𝐈𝐁𝐎 𝐡𝐲𝐩𝐨𝐭𝐡𝐞𝐬𝐢𝐬 𝐚𝐧𝐝 𝐛𝐫𝐞𝐚𝐭𝐡 𝐭𝐞𝐬𝐭𝐢𝐧𝐠: 𝐀 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐩𝐫𝐚𝐜𝐭𝐢𝐜𝐞 𝐮𝐩𝐝𝐚𝐭𝐞 𝐞𝐧𝐝𝐨𝐫𝐬𝐞𝐝 𝐛𝐲 𝐭𝐡𝐞 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐬𝐨𝐜𝐢𝐞𝐭𝐲 𝐨𝐟 𝐧𝐞𝐮𝐫𝐨𝐠𝐚𝐬𝐭𝐫𝐨𝐞𝐧𝐭𝐞𝐫𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 𝐦𝐨𝐭𝐢𝐥𝐢𝐭𝐲 (𝐄𝐒𝐍𝐌) 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐀𝐦𝐞𝐫𝐢𝐜𝐚𝐧 𝐧𝐞𝐮𝐫𝐨𝐠𝐚𝐬𝐭𝐫𝐨𝐞𝐧𝐭𝐞𝐫𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 𝐦𝐨𝐭𝐢𝐥𝐢𝐭𝐲 𝐬𝐨𝐜𝐢𝐞𝐭𝐲 (𝐀𝐍𝐌𝐒)

Key points
- The 𝐒𝐈𝐁𝐎-𝐈𝐁𝐒 𝐡𝐲𝐩𝐨𝐭𝐡𝐞𝐬𝐢𝐬 has stimulated significant research into the role of the microbiota in symptoms of DBGI but 𝐫𝐞𝐦𝐚𝐢𝐧𝐬 𝐮𝐧𝐩𝐫𝐨𝐯𝐞𝐧.
- This hypothesis has resulted in 𝐬𝐞𝐫𝐢𝐨𝐮𝐬 𝐮𝐧𝐢𝐧𝐭𝐞𝐧𝐝𝐞𝐝 𝐜𝐨𝐧𝐬𝐞𝐪𝐮𝐞𝐧𝐜𝐞𝐬, namely the use of poorly validated breath tests to diagnose SIBO and the resulting injudicious use of antibiotics.
- The lactulose breath test (LBT) is primarily a measure of intestinal transit and has 𝐯𝐞𝐫𝐲 𝐥𝐨𝐰 𝐬𝐞𝐧𝐬𝐢𝐭𝐢𝐯𝐢𝐭𝐲 𝐚𝐧𝐝 𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜𝐢𝐭𝐲 to diagnose SIBO.
- The glucose breath test (GBT) has better performance characteristics if the pre-test probability is high, as found in conditions underlying classical SIBO, but also has a 𝐡𝐢𝐠𝐡 𝐟𝐚𝐥𝐬𝐞-𝐩𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐫𝐚𝐭𝐞 𝐢𝐧 𝐃𝐆𝐁𝐈.
- Future studies in DGBI are needed to better understand the impact of bacterial communities, their metabolites, and diet-host interactions in the small and large intestine on DGBI symptoms and move away from the sole focus on absolute numbers of bacteria.

This mess and the huge costs to show that SIBO and IBS are unrelated was originally created by Dr. Mark Pimente

https://onlinelibrary.wiley.com/doi/10.1111/nmo.14817

Edited July 31, 20251 yr by Selfsimilar